Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Fast Track Articles
  5. Fast Track Article
image of Astaxanthin Alleviates Chronic Prostatitis via the ERK1/2 Signaling Pathway: Evidence from Network Pharmacology and Experimental Validation

Abstract

Background

Astaxanthin (AST) has been widely recognized for its therapeutic potential in chronic inflammatory ailments. This study investigates the therapeutic efficacy and underlying mechanisms of AST in the management of chronic prostatitis (CP).

Methods

Male Sprague-Dawley (SD) rats were randomly divided into control, complete Freund's adjuvant (CFA), and CFA + AST groups. CFA was used to induce the CP model, and saline was used for the control group. Inflammation of the prostate was detected 28 days after oral administration of AST. qRT-PCR and ELISA were used to detect pro-inflammatory factors in RWPE-1 and WPMY-1 cells. Potential targets of AST for CP were explored by network pharmacology, and related proteins were detected by Western blotting.

Results

Oral administration of AST alleviated the increase in prostate stroma and reduced inflammatory cell infiltration in CP rats. The IC of AST-treated RWPE-1 and WPMY-1 cells for 48 h were 171 and 212.1 μM, respectively. AST pretreatment reduced IL-6 and IL-8 expression in these cells. PPI network, GO, and KEGG enrichment analyses suggested that the anti-inflammatory effect of AST was associated with the ERK1/2 pathway. Western blotting showed that AST inhibited ERK1/2 phosphorylation. In addition, AST and ERK1/2 pathway inhibitors (U0126) synergistically inhibited LPS-induced inflammation in prostate cells.

Conclusion

Our study identified the potential of AST in the treatment of CP. However, subsequent randomized controlled trials are needed to validate its clinical efficacy.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073331381240923080152
2024-10-09
2024-11-26

  • From This Site

    /content/journals/cchts/10.2174/0113862073331381240923080152
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Pena V.N. Engel N. Gabrielson A.T. Rabinowitz M.J. Herati A.S. Diagnostic and Management Strategies for Patients with Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Drugs Aging 2021 38 10 845 886 10.1007/s40266‑021‑00890‑2 34586623
    [Google Scholar]
  2. Krieger JN Lee SW Jeon J Cheah PY Liong ML Riley DE Epidemiology of prostatitis. Int J Antimicrob Agents. 2008 31 S1 S85 90 10.1016/j.ijantimicag.2007.08.028
    [Google Scholar]
  3. Krieger J.N. Nyberg L. Jr Nickel J.C. NIH consensus definition and classification of prostatitis. JAMA 1999 282 3 236 237 10.1001/jama.282.3.236 10422990
    [Google Scholar]
  4. Lee S.W.H. Liong M.L. Yuen K.H. Leong W.S. Cheah P.Y. Khan N.A.K. Krieger J.N. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology 2008 71 1 79 84 10.1016/j.urology.2007.08.043 18242370
    [Google Scholar]
  5. Rees J. Abrahams M. Doble A. Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015 116 4 509 525 10.1111/bju.13101 25711488
    [Google Scholar]
  6. Nickel J.C. Downey J. Clark J. Casey R.W. Pommerville P.J. Barkin J. Steinhoff G. Brock G. Patrick A.B. Flax S. Goldfarb B. Palmer B.W. Zadra J. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003 62 4 614 617 10.1016/S0090‑4295(03)00583‑1 14550427
    [Google Scholar]
  7. Alexander R.B. Propert K.J. Schaeffer A.J. Landis J.R. Nickel J.C. O’Leary M.P. Pontari M.A. McNaughton-Collins M. Shoskes D.A. Comiter C.V. Datta N.S. Fowler J.E. Jr Nadler R.B. Zeitlin S.I. Knauss J.S. Wang Y. Kusek J.W. Nyberg L.M. Jr Litwin M.S. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann. Intern. Med. 2004 141 8 581 589 10.7326/0003‑4819‑141‑8‑200410190‑00005 15492337
    [Google Scholar]
  8. Nickel J.C. Krieger J.N. McNaughton-Collins M. Anderson R.U. Pontari M. Shoskes D.A. Litwin M.S. Alexander R.B. White P.C. Berger R. Nadler R. O’Leary M. Liong M.L. Zeitlin S. Chuai S. Landis J.R. Kusek J.W. Nyberg L.M. Schaeffer A.J. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N. Engl. J. Med. 2008 359 25 2663 2673 10.1056/NEJMoa0803240 19092152
    [Google Scholar]
  9. Shoskes D.A. Zeitlin S.I. Shahed A. Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology 1999 54 6 960 963 10.1016/S0090‑4295(99)00358‑1 10604689
    [Google Scholar]
  10. Wagenlehner F.M.E. Schneider H. Ludwig M. Schnitker J. Brähler E. Weidner W. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur. Urol. 2009 56 3 544 551 10.1016/j.eururo.2009.05.046 19524353
    [Google Scholar]
  11. Davinelli S. Nielsen M.E. Scapagnini G. Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review. Nutrients 2018 10 4 522 10.3390/nu10040522 29690549
    [Google Scholar]
  12. Zhou P. Li M. Shen B. Yao Z. Bian Q. Ye L. Yu H. Directed Coevolution of β-Carotene Ketolase and Hydroxylase and Its Application in Temperature-Regulated Biosynthesis of Astaxanthin. J. Agric. Food Chem. 2019 67 4 1072 1080 10.1021/acs.jafc.8b05003 30606005
    [Google Scholar]
  13. Kohandel Z. Farkhondeh T. Aschner M. Pourbagher-Shahri A.M. Samarghandian S. Anti-inflammatory action of astaxanthin and its use in the treatment of various diseases. Biomed. Pharmacother. 2022 145 112179 10.1016/j.biopha.2021.112179 34736076
    [Google Scholar]
  14. Park J.S. Chyun J.H. Kim Y.K. Line L.L. Chew B.P. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr. Metab. (Lond.) 2010 7 1 18 10.1186/1743‑7075‑7‑18 20205737
    [Google Scholar]
  15. Andersen L.P. Holck S. Kupcinskas L. Kiudelis G. Jonaitis L. Janciauskas D. Permin H. Wadström T. Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. FEMS Immunol. Med. Microbiol. 2007 50 2 244 248 10.1111/j.1574‑695X.2007.00257.x 17521392
    [Google Scholar]
  16. Coombes J.S. Sharman J.E. Fassett R.G. Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). Am. J. Clin. Nutr. 2016 103 1 283 289 10.3945/ajcn.115.115477 26675778
    [Google Scholar]
  17. Liu Y.F. Xie W.J. Xi P. Zhang Z.C. Chen R. Fu S.Q. Lei K.Y. Liu J. Cheng X.F. Nie Y.C. Yang X.R. Ma M. Sun T. Gong B.B. Astaxanthin alleviates chronic prostatitis/chronic pelvic pain syndrome by increasing colonization of Akkermansia muciniphila in the intestine. Phytomedicine 2024 123 155249 10.1016/j.phymed.2023.155249 38056144
    [Google Scholar]
  18. Lucas R.M. Luo L. Stow J.L. ERK1/2 in immune signalling. Biochem. Soc. Trans. 2022 50 5 1341 1352 10.1042/BST20220271 36281999
    [Google Scholar]
  19. Brereton C.F. Sutton C.E. Lalor S.J. Lavelle E.C. Mills K.H. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immun. 2009 183 3 1715 23
    [Google Scholar]
  20. de Launay D. van de Sande M.G.H. de Hair M.J.H. Grabiec A.M. van de Sande G.P.M. Lehmann K.A. Wijbrandts C.A. van Baarsen L.G.M. Gerlag D.M. Tak P.P. Reedquist K.A. Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): A prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann. Rheum. Dis. 2012 71 3 415 423 10.1136/ard.2010.143529 21953337
    [Google Scholar]
  21. van ’t Wout E.F.A. Dickens J.A. van Schadewijk A. Haq I. Kwok H.F. Ordóñez A. Murphy G. Stolk J. Lomas D.A. Hiemstra P.S. Marciniak S.J. Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin. Hum. Mol. Genet. 2014 23 4 929 941 10.1093/hmg/ddt487 24097797
    [Google Scholar]
  22. Meng L.Q. Yang F.Y. Wang M.S. Shi B.K. Chen D.X. Chen D. Zhou Q. He Q.B. Ma L.X. Cheng W.L. Xing N.Z. Quercetin protects against chronic prostatitis in rat model through NF‐κB and MAPK signaling pathways. Prostate 2018 78 11 790 800 10.1002/pros.23536 29654614
    [Google Scholar]
  23. Kim Y.H. Koh H.K. Kim D.S. Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. Int. Immunopharmacol. 2010 10 12 1560 1572 10.1016/j.intimp.2010.09.007 20932499
    [Google Scholar]
  24. Zhao L. Tao X. Song T. Astaxanthin alleviates neuropathic pain by inhibiting the MAPKs and NF-κB pathways. Eur. J. Pharmacol. 2021 912 174575 10.1016/j.ejphar.2021.174575 34673033
    [Google Scholar]
  25. Liu Y. Fu S. Zhang Z. Wang S. Cheng X. Li Z. Ding Y. Sun T. Ma M. GRAMD1A Is a Biomarker of Kidney Renal Clear Cell Carcinoma and Is Associated with Immune Infiltration in the Tumour Microenvironment. Dis. Markers 2022 2022 1 25 10.1155/2022/5939021 35860689
    [Google Scholar]
  26. Yang F. Meng L. Han P. Chen D. Wang M. Jiang Y. Wu Y. Wu Y. Xing N. New therapy with XLQ ® to suppress chronic prostatitis through its anti‐inflammatory and antioxidative activities. J. Cell. Physiol. 2019 234 10 17570 17577 10.1002/jcp.28380 30790289
    [Google Scholar]
  27. Cui G. Li L. Xu W. Wang M. Jiao D. Yao B. Xu K. Chen Y. Yang S. Long M. Li P. Guo Y. Astaxanthin Protects Ochratoxin A-Induced Oxidative Stress and Apoptosis in the Heart via the Nrf2 Pathway. Oxid. Med. Cell. Longev. 2020 2020 1 11 10.1155/2020/7639109 32190177
    [Google Scholar]
  28. Dilli D. Taşoğlu İ. Sarı E. Akduman H. Yumuşak N. Tümer N.B. Therapeutic Role of Astaxanthin and Resveratrol in an Experimental Rat Model of Supraceliac Aortic Ischemia-Reperfusion. Am. J. Perinatol. 2022 35644129
    [Google Scholar]
  29. Liu S. Zhao F. Deng Y. Zeng Y. Yan B. Guo J. Gao Q. Investigating the multi-target therapeutic mechanism of Guihuang formula on Chronic Prostatitis. J. Ethnopharmacol. 2022 294 115386 10.1016/j.jep.2022.115386 35580771
    [Google Scholar]
  30. Liu Z. Guo F. Wang Y. Li C. Zhang X. Li H. Diao L. Gu J. Wang W. Li D. He F. BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine. Sci. Rep. 2016 6 1 21146 10.1038/srep21146 26879404
    [Google Scholar]
  31. Grondin C.J. Davis A.P. Wiegers J.A. Wiegers T.C. Sciaky D. Johnson R.J. Mattingly C.J. Predicting molecular mechanisms, pathways, and health outcomes induced by Juul e-cigarette aerosol chemicals using the Comparative Toxicogenomics Database. Current Research in Toxicology 2021 2 272 281 10.1016/j.crtox.2021.08.001 34458863
    [Google Scholar]
  32. Wang X. Shen Y. Wang S. Li S. Zhang W. Liu X. Lai L. Pei J. Li H. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017 45 W1 W356 W360 10.1093/nar/gkx374 28472422
    [Google Scholar]
  33. Keiser M.J. Roth B.L. Armbruster B.N. Ernsberger P. Irwin J.J. Shoichet B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007 25 2 197 206 10.1038/nbt1284 17287757
    [Google Scholar]
  34. Daina A. Michielin O. Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019 47 W1 W357 W364 10.1093/nar/gkz382 31106366
    [Google Scholar]
  35. Stelzer G. Dalah I. Stein T. Satanower Y. Rosen N. Nativ N. Oz-Levi D. Olender T. Belinky F. Bahir I. Krug H. Perco P. Mayer B. Kolker E. Safran M. Lancet D. In-silico human genomics with GeneCards. Hum. Genomics 2011 5 6 709 717 10.1186/1479‑7364‑5‑6‑709 22155609
    [Google Scholar]
  36. Stelzer G. Plaschkes I. Oz-Levi D. Alkelai A. Olender T. Zimmerman S. VarElect: the phenotype-based variation prioritizer of the GeneCards Suite. BMC Genomics. 2016 17 Suppl 2 444 10.1186/s12864‑016‑2722‑2
    [Google Scholar]
  37. Sobrinho Santos E.M. Almeida A.C. Santos H.O. Cangussu A.R. Costa K.S. Alves J.N. Bertucci Barbosa L.C. Souza Aguiar R.W. Mechanism of Brassica oleracea performance in bovine infectious mastitis by bioinformatic analysis. Microb. Pathog. 2019 129 19 29 10.1016/j.micpath.2019.01.029 30685362
    [Google Scholar]
  38. Pan Q. Zhou R. Su M. Li R. The Effects of Plumbagin on Pancreatic Cancer: A Mechanistic Network Pharmacology Approach. Med. Sci. Monit. 2019 25 4648 4654 10.12659/MSM.917240 31230062
    [Google Scholar]
  39. Decherchi S. Cavalli A. Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation. Chem. Rev. 2020 120 23 12788 12833 10.1021/acs.chemrev.0c00534 33006893
    [Google Scholar]
  40. Liu J. Liu J. Tong X. Peng W. Wei S. Sun T. Wang Y. Zhang B. Li W. Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis. Drug Des. Devel. Ther. 2021 15 3255 3276 10.2147/DDDT.S319786 34349502
    [Google Scholar]
  41. Yang C. You L. Yin X. Liu Y. Leng X. Wang W. Sai N. Ni J. Heterophyllin B Ameliorates Lipopolysaccharide-Induced Inflammation and Oxidative Stress in RAW 264.7 Macrophages by Suppressing the PI3K/Akt Pathways. Molecules 2018 23 4 717 10.3390/molecules23040717 29561811
    [Google Scholar]
  42. Liu J. Liu L. Zhang G. Peng X. Poria cocos polysaccharides attenuate chronic nonbacterial prostatitis by targeting the gut microbiota: Comparative study of Poria cocos polysaccharides and finasteride in treating chronic prostatitis. Int. J. Biol. Macromol. 2021 189 346 355 10.1016/j.ijbiomac.2021.08.139 34428489
    [Google Scholar]
  43. He Y. Gao J-L. Chen N-W. Jin J. Xu H. Wei X-C. Wu L-F. Xie W-H. Cheng Y-X. Effect of thermophilic bacterium HB27 manganese superoxide dismutase in a rat model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Asian J. Androl. 2022 24 3 323 331 10.4103/aja202157 34747725
    [Google Scholar]
  44. Penna G. Mondaini N. Amuchastegui S. Degli Innocenti S. Carini M. Giubilei G. Fibbi B. Colli E. Maggi M. Adorini L. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol. 2007 51 2 524 533 10.1016/j.eururo.2006.07.016 16905241
    [Google Scholar]
  45. Cai T. Verze P. La Rocca R. Palmieri A. Tiscione D. Luciani L.G. Mazzoli S. Mirone V. Malossini G. The Clinical Efficacy of Pollen Extract and Vitamins on Chronic Prostatitis/Chronic Pelvic Pain Syndrome Is Linked to a Decrease in the Pro-Inflammatory Cytokine Interleukin-8. World J. Mens Health 2017 35 2 120 128 10.5534/wjmh.2017.35.2.120 28497911
    [Google Scholar]
  46. Chen L. Bian Z. Chen J. Meng J. Zhang M. Liang C. Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis. Cytokine 2021 141 155440 10.1016/j.cyto.2021.155440 33550164
    [Google Scholar]
  47. Matsushima K. Yang D. Oppenheim J.J. Interleukin-8: An evolving chemokine. Cytokine 2022 153 155828 10.1016/j.cyto.2022.155828 35247648
    [Google Scholar]
  48. Hu C. Yang H. Zhao Y. Chen X. Dong Y. Li L. Dong Y. Cui J. Zhu T. Zheng P. Lin C.S. Dai J. The role of inflammatory cytokines and ERK1/2 signaling in chronic prostatitis/chronic pelvic pain syndrome with related mental health disorders. Sci. Rep. 2016 6 1 28608 10.1038/srep28608 27334333
    [Google Scholar]
  49. Yang L. Xie X. Tu Z. Fu J. Xu D. Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 2021 6 1 255 10.1038/s41392‑021‑00679‑0 34234112
    [Google Scholar]
  50. Yi J. Pan J. Zhang S. Mao W. Wang J. Wang W. Yan Z. Jiedu Huoxue decoction improves chronic abacterial prostatitis/chronic pelvic pain syndrome through activating Wnt/GSKβ/β-catenin signaling pathway and alleviating apoptosis. Biomed. Pharmacother. 2022 149 112830 10.1016/j.biopha.2022.112830 35306428
    [Google Scholar]
  51. Liu H. Zhu X. Cao X. Chi A. Dai J. Wang Z. Deng C. Zhang M. IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity. Stem Cell Res. Ther. 2021 12 1 514 10.1186/s13287‑021‑02579‑0 34563249
    [Google Scholar]
  52. Du H.X. Yue S.Y. Niu D. Liu C. Zhang L.G. Chen J. Chen Y. Guan Y. Hua X.L. Li C. Chen X.G. Zhang L. Liang C.Z. Gut Microflora Modulates Th17/Treg Cell Differentiation in Experimental Autoimmune Prostatitis via the Short-Chain Fatty Acid Propionate. Front. Immunol. 2022 13 915218 10.3389/fimmu.2022.915218 35860242
    [Google Scholar]
  53. Hua X. Ge S. Zhang M. Mo F. Zhang L. Zhang J. Yang C. Tai S. Chen X. Zhang L. Liang C. Pathogenic Roles of CXCL10 in Experimental Autoimmune Prostatitis by Modulating Macrophage Chemotaxis and Cytokine Secretion. Front. Immunol. 2021 12 706027 10.3389/fimmu.2021.706027 34659199
    [Google Scholar]
  54. Yu J. Hu Q. Liu J. Luo J. Liu L. Peng X. Metabolites of gut microbiota fermenting Poria cocos polysaccharide alleviates chronic nonbacterial prostatitis in rats. Int. J. Biol. Macromol. 2022 209 Pt B 1593 604 10.1016/j.ijbiomac.2022.04.029
    [Google Scholar]
  55. Yi J. Pan J. Zhang S. Mao W. Wang J. Wang W. Improvement of chronic non-bacterial prostatitis by Jiedu Huoxue decoction through inhibiting TGF-β/SMAD signaling pathway. Biomed Pharmacother. 2022 152 113193
    [Google Scholar]
  56. Zhou Y. Wang J. Han J. Feng J. Guo K. Du F. Chen W. Li Y. Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway. Inflamm. Res. 2022 71 4 449 460 10.1007/s00011‑022‑01544‑8 35279736
    [Google Scholar]
  57. Che H. Li Q. Zhang T. Wang D. Yang L. Xu J. Yanagita T. Xue C. Chang Y. Wang Y. Effects of Astaxanthin and Docosahexaenoic-Acid-Acylated Astaxanthin on Alzheimer’s Disease in APP/PS1 Double-Transgenic Mice. J. Agric. Food Chem. 2018 66 19 4948 4957 10.1021/acs.jafc.8b00988 29695154
    [Google Scholar]
  58. Li J. Xia Y. Liu T. Wang J. Dai W. Wang F. Zheng Y. Chen K. Li S. Abudumijiti H. Zhou Z. Wang J. Lu W. Zhu R. Yang J. Zhang H. Yin Q. Wang C. Zhou Y. Lu J. Zhou Y. Guo C. Protective effects of astaxanthin on ConA-induced autoimmune hepatitis by the JNK/p-JNK pathway-mediated inhibition of autophagy and apoptosis. PLoS One 2015 10 3 e0120440 10.1371/journal.pone.0120440 25761053
    [Google Scholar]
  59. Liu G. Shi Y. Peng X. Liu H. Peng Y. He L. Astaxanthin attenuates adriamycin-induced focal segmental glomerulosclerosis. Pharmacology 2015 95 3-4 193 200 10.1159/000381314 25924598
    [Google Scholar]
  60. Yasui Y. Hosokawa M. Mikami N. Miyashita K. Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem. Biol. Interact. 2011 193 1 79 87 10.1016/j.cbi.2011.05.006 21621527
    [Google Scholar]
  61. Abdelzaher L.A. Imaizumi T. Suzuki T. Tomita K. Takashina M. Hattori Y. Astaxanthin alleviates oxidative stress insults-related derangements in human vascular endothelial cells exposed to glucose fluctuations. Life Sci. 2016 150 24 31 10.1016/j.lfs.2016.02.087 26924495
    [Google Scholar]
  62. Fujiwara N. Kobayashi K. Macrophages in Inflammation. Curr. Drug Targets Inflamm. Allergy 2005 4 3 281 286 10.2174/1568010054022024 16101534
    [Google Scholar]
  63. Curciarello R. Canziani K.E. Docena G.H. Muglia C.I. Contribution of Non-immune Cells to Activation and Modulation of the Intestinal Inflammation. Front. Immunol. 2019 10 647 10.3389/fimmu.2019.00647 31024529
    [Google Scholar]
  64. Xie D. He F. Wang X. Wang X. Jin Q. Jin J. Diverse Krill Lipid Fractions Differentially Reduce LPS-Induced Inflammatory Markers in RAW264.7 macrophages in vitro. Foods 2021 10 11 2887 10.3390/foods10112887 34829168
    [Google Scholar]
  65. Nogales C. Mamdouh Z.M. List M. Kiel C. Casas A.I. Schmidt H.H.H.W. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 2022 43 2 136 150 10.1016/j.tips.2021.11.004 34895945
    [Google Scholar]
  66. Zhang G. Li Q. Chen Q. Su S. Network pharmacology: a new approach for chinese herbal medicine research. Evid. Based Complement. Alternat. Med. 2013 2013 1 9 10.1155/2013/621423 23762149
    [Google Scholar]
  67. Greenblatt M.B. Shim J.H. Glimcher L.H. Mitogen-activated protein kinase pathways in osteoblasts. Annu. Rev. Cell Dev. Biol. 2013 29 1 63 79 10.1146/annurev‑cellbio‑101512‑122347 23725048
    [Google Scholar]
  68. Tian Q.X. Zhang Z.H. Ye Q.L. Xu S. Hong Q. Xing W.Y. Chen L. Yu D.X. Xu D.X. Xie D.D. Melatonin Inhibits Migration and Invasion in LPS-Stimulated and -Unstimulated Prostate Cancer Cells Through Blocking Multiple EMT-Relative Pathways. J. Inflamm. Res. 2021 14 2253 2265 10.2147/JIR.S305450 34079331
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073331381240923080152
Loading
Astaxanthin Alleviates Chronic Prostatitis via the ERK1/2 Signaling Pathway: Evidence from Network Pharmacology and Experimental Validation
Bentham Science Publishers ; https://doi.org/10.2174/0113862073331381240923080152
/content/journals/cchts/10.2174/0113862073331381240923080152
/content/journals/cchts/10.2174/0113862073331381240923080152
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: RWPE-1 cells ; chronic prostatitis ; Astaxanthin ; inflammation ; molecular docking ; WPMY-1 cells

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test